Boston Scientific: PROMUS Element Stent Demonstrates Excellent Long-Term Safety and Effectiveness in PLATINUM Small Vessel Study
Boston Scientific Corporation (NYSE: BSX) announces two-year results from the PLATINUM Small Vessel study, demonstrating excellent safety and effectiveness outcomes for the 2.25 mm PROMUS Element™ Everolimus-Eluting Platinum Chromium (PtCr) Stent System in treating de novo coronary lesions in small coronary vessels. Analysis of the data was presented today at the annual EuroPCR Scientific Program in Paris.
"The PLATINUM Small Vessel data continue to demonstrate very low revascularization rates, with no myocardial infarction or stent thrombosis through two years of follow up in patients treated with the 2.25 mm PROMUS Element Stent," said Ian Meredith, Professor and Director of MonashHeart, at Monash Medical Centre in Melbourne, Australia, and co-principal investigator for the PLATINUM clinical program. "These long-term results are impressive, especially considering the small vessel diameters that were evaluated in this study."
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.